China News Service, March 21. According to the WeChat public account of the National Medical Insurance Bureau, on March 21, the Office of the National Medical Insurance Bureau issued the "Notice on Effectively Doing a Good Job in the Current Epidemic Prevention and Control of Medical Security". Adjust the new crown treatment drugs included in the scope of medical insurance payment.
The notice pointed out that for the newly added drugs in the "Diagnosis and Treatment Plan (Trial Version 9)", all provincial medical security departments should refer to the "Notice of the National Medical Security Administration and the Ministry of Finance on Doing a Good Job in Medical Insurance for Pneumonia Infected by Novel Coronavirus" (National Medical Insurance (2020) No. 5), which should be temporarily included in the payment scope of the medical insurance fund in the province; for the drugs that are transferred out of the "Diagnosis and Treatment Plan (Trial Version 9)" and are not included in the basic medical insurance catalog, the provincial medical security departments The medical insurance payment shall be stopped from the date of publication of the "Diagnosis and Treatment Plan (Trial Version 9)".
All provincial medical security departments should do a good job in the work of adding new drugs to the Internet. For drugs that have not been listed on the Internet, medical institutions are allowed to purchase offline first for emergency use.
The newly added naimatevir tablets/ritonavir tablets in the "Diagnosis and Treatment Plan (Trial Version 9)" shall be purchased by medical institutions at the price agreed between the enterprise and relevant departments, and the medical insurance department shall pay according to regulations.
The notice proposes that the new coronavirus antigen detection reagents and corresponding detection items should be temporarily included in the province's basic medical insurance medical service project catalog according to the procedures.
The relevant expenses incurred by the insured in the designated primary medical institutions shall be paid in accordance with the current regulations of the overall planning area, and the expenses of purchasing testing reagents at the designated retail pharmacies can be paid using personal accounts.
All provincial medical security departments shall continue to standardize and optimize public medical institutions with reference to the "Letter of the Office of the National Medical Security Administration on Local Opinions on Temporary New Coronavirus Antigen Testing Items and Related Matters" (Medical Insurance Office Letter [2022] No. 11) Pricing policy for providing COVID-19 antigen testing services.
Centralized pharmaceutical procurement agencies in various regions should do a good job in the online purchase of novel coronavirus antigen detection reagents, actively promote online purchases, and rely on the national unified medical insurance information platform for information sharing.
At the same time, it will strengthen the calculation and monitoring, and coordinate the promotion of price, procurement, payment and information system transformation.
The notice requires that medical security departments at all levels should follow the requirements of a series of documents such as the “Notice of the National Medical Security Administration and the Ministry of Finance on Doing a Good Job in Medical Insurance for Pneumonia Infected by Novel Coronavirus” (National Medical Insurance Power [2020] No. 5) and other series of documents. Work measures, continue to implement policies such as comprehensive protection of medical expenses for confirmed patients.
Support the normal operation of medical institutions in severely affected areas, and prepay part of the new crown treatment funds according to procedures if necessary.
Do a solid job in ensuring the cost of new coronavirus vaccines and vaccinations, conscientiously implement the price policy for nucleic acid and antigen testing items, implement "long-term prescription", Internet diagnosis and treatment and other settlement and reimbursement policies, ensure the implementation of various epidemic prevention and control medical security policies, and reduce the number of insured patients The number of visits to medical institutions for dispensing medicines can effectively reduce the safety risk of the spread of the epidemic.